TFA
ECYT

Transamerica Financial Advisors’s Endocyte, Inc. Common Stock ECYT Stock Holding History

Transamerica Financial Advisors’s Portfolio ECYT Stock Details ECYT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-1,000
Closed -$5K – 879
2015
Q4 		$5K Hold
1,000
– – ﹤0.01% 679
2015
Q3 		$5K Buy
+1,000
New +$5.23K ﹤0.01% 661

Other funds holding ECYT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Pinnacle Associates New York $7.78B AUM 45.07% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
HCMT
Highland Capital Management (Texas) Dallas, Texas $39M AUM
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Transamerica Financial Advisors's ECYT Position: Q1 2016 in Review

Transamerica Financial Advisors sold out of Endocyte, Inc. Common Stock (ECYT) in Q1 2016, closing a stake of 1,000 shares — an estimated $5K sold.

Transamerica Financial Advisors first reported a position in ECYT in Q3 2015 and held it in 2 quarters. The position peaked at $5K in Q4 2015. 97 funds tracked by Wall St. Rank hold ECYT as of Q1 2016.

  • Transamerica Financial Advisors reported no remaining Endocyte, Inc. Common Stock position as of Q1 2016 after selling out during the quarter.
  • Transamerica Financial Advisors sold 1,000 Endocyte, Inc. Common Stock shares in Q1 2016, an estimated $5K.
  • Transamerica Financial Advisors first reported a position in Endocyte, Inc. Common Stock in Q3 2015 and held it in 2 quarters.
  • Transamerica Financial Advisors's Endocyte, Inc. Common Stock position peaked at $5K in Q4 2015.
  • 97 funds tracked by Wall St. Rank held Endocyte, Inc. Common Stock as of Q1 2016.

Based on Transamerica Financial Advisors's 13F filing for Q1 2016, filed 21 Apr 2016.